Ph 2, Double-Masked, Randomized, Parallel, Sham Surgery/Placebo Control, Multi-Center Study to Evaluate Systemic IMT Regimens as Graft Rejection Prophylaxis Following Transplantation of hESC Derived RPE Cells in Patients With AMD
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 29 Jul 2017
At a glance
- Drugs MA09 retinal pigment epithelial cell replacement therapy-Astellas Pharma (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions
- Acronyms PORTRAY
- Sponsors Astellas Institute for Regenerative Medicine
- 25 Jul 2017 Planned End Date changed from 1 May 2019 to 5 May 2019.
- 25 Jul 2017 Planned primary completion date changed from 1 May 2017 to 5 May 2017.
- 25 Jul 2017 Status changed from discontinued to withdrawn prior to enrolment.